Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution
| Autor: | B.J. Vincke, J. W. Dobbie, John P. Neoptolemos, N. Dombros, David J. Kerr, P. Van-Geene, D. R. Ferry, Annie M. Young, George Fountzilas, D. I. D. El Eini, Andrew Stanley, John R. Gilbert, M. Sherman |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Carcinosis medicine.medical_treatment Peritonitis Icodextrin Peritoneal dialysis Peritoneal Neoplasm Peritoneal cavity Drug Delivery Systems Bolus (medicine) Pharmacokinetics medicine Humans Infusions Parenteral Peritoneal Neoplasms Aged Drug Carriers business.industry Middle Aged medicine.disease Surgery medicine.anatomical_structure Oncology Anesthesia Female Fluorouracil business Peritoneal Dialysis Follow-Up Studies Research Article |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.1996.672 |
| Popis: | A novel peritoneal carrier solution, Icodextrin 20 (7.5%), has allowed exploration of prolonged, intraperitoneal (i.p.) infusion of the cytotoxic drug 5-fluorouracil (5-FU). A phase I and pharmacokinetic study was performed to determine the toxicities and maximum tolerated dose of prolonged and continuous intraperitoneal 5-FU in patients with peritoneal carcinomatosis. Seventeen patients were entered into this study. Each patient had a Tenckhoff catheter placed into the peritoneal cavity under general anaesthetic. After initial flushing and gradual increase in exchange volumes with Icodextrin 20, 5-FU was administered daily from Monday to Friday, 50% as a bolus in the exchange bag and 50% in an elastomeric infusor device delivering continuous 5-FU to the peritoneal cavity at 2 ml h-1. Treatment was continued for 12 weeks or until intolerable toxicity developed. Abdominal pain and infective peritonitis proved to be the main dose-limiting toxicities. Initial problems with infective peritonitis were overcome by redesign of the delivery system, and it proved possible to deliver 300 mg m-2 5-FU daily (5 days per week) for 12 weeks. Pharmacokinetic studies showed i.p. steady-state 5-FU concentrations (mean 47 500 ng ml-1) that were > 1000-fold higher than systemic venous levels (mean 30 ng ml-1). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|